Baystate Wealth Management’s NovoCure NVCR Stock Holding History

Baystate Wealth Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-8	Closed	-$1K	–	793
2020 Q4	$1K	Buy	+8	New	+$1.09K	﹤0.01%	636

Other funds holding NVCR

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baystate Wealth Management's NVCR Position: Q1 2021 in Review

Baystate Wealth Management sold out of NovoCure (NVCR) in Q1 2021, closing a stake of 8 shares — an estimated $1K sold.

Baystate Wealth Management first reported a position in NVCR in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 327 funds tracked by Wall St. Rank hold NVCR as of Q1 2021.

Baystate Wealth Management reported no remaining NovoCure position as of Q1 2021 after selling out during the quarter.
Baystate Wealth Management sold 8 NovoCure shares in Q1 2021, an estimated $1K.
Baystate Wealth Management first reported a position in NovoCure in Q4 2020 and held it in 1 quarter.
Baystate Wealth Management's NovoCure position peaked at $1K in Q4 2020.
327 funds tracked by Wall St. Rank held NovoCure as of Q1 2021.

Based on Baystate Wealth Management's 13F filing for Q1 2021, filed 21 Apr 2021.